A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

June 30, 2015

Conditions

Diabetes Mellitus Type 1

Interventions

DRUG

BioChaperone human insulin

Single dose of 0.2 U/kg body weight injected subcutaneously

DRUG

Huminsulin® Normal

Single dose of 0.2 U/kg body weight injected subcutaneously

DRUG

Humalog®

Single dose of 0.2 U/kg body weight injected subcutaneously

Trial Locations (1)

Profil GmbH, Neuss